Alkem Foundation, IIT Bombay collaborate to set up advanced research centre for immunotherapeutics, regenerative medicines

Alkem Foundation will contribute a substantial 20-25% of its cumulative CSR obligations over seven years on this research centre.

The partnership brings together Alkem’s pharmaceutical industry insights and experience in developing healthcare solutions, and IIT Bombay’s expertise in biomedical engineering, biosciences, and translational research, along with a pool of globally trained faculty, to create a distinctive innovation and translation ecosystem.

As per the release, the research centre is being developed with an objective of building a comprehensive ecosystem that enables innovation, research, and skill development in complex and underserved therapy areas, and bridging critical gaps in infrastructure, talent, and translational capability, especially in the area of high precision medicines. The initiative will augment IIT Bombay’s multidisciplinary approach to healthcare integrating biology, engineering, and data science to advance human health. The Institute’s pioneering research spans biotechnology, biomedical engineering, and cell and gene therapy, forming the foundation for next-generation immuno-therapeutics and regenerative medicine.

The new research centre will expand into emerging areas such as gene editing and biomaterials and technology to bolster immuno-therapeutics and regenerative medicines using unique models based on futuristic techniques for delivery and edition. It will also serve as a training and incubation hub for clinician-scientists and biotech entrepreneurs. It will draw upon IIT Bombay's core faculty and have mentors from IIT Bombay and Alkem, as well as global experts from premier universities, who will advise on the research programmes.

Madhurima Singh, Executive Director and Chairperson of the CSR and Sustainability Committee, Alkem, said, “At Alkem, we understand the critical role of scientific advancement and transformative research in addressing unmet medical needs. Despite government encouragement, only a small share of corporate CSR spending in India goes towards R&D. We saw it as our responsibility to go beyond business and support R&D in the important field of immuno-therapeutics and regenerative medicines through CSR. We are pleased to partner with IIT Bombay, a prestigious institution that has been at the forefront of India’s innovation and self-reliance efforts, to develop advanced and cost-effective treatments that can improve both lifespan and quality of life. This partnership reflects our shared commitment to developing healthcare solutions by India for India and the world.”

Prof. Shireesh B. Kedare, Director, IIT Bombay, said, "We are delighted to partner with Alkem Foundation in this transformative initiative. IIT Bombay's strong foundation in biotechnology, biomedical engineering, and regenerative sciences positions us to translate cutting-edge research into real-world healthcare impact. This collaboration will foster clinical breakthroughs that lead to affordable therapies, reduce dependence on imports, and take us a step further in India's journey toward self-reliance in healthcare innovation."

Together, IIT Bombay and Alkem Foundation aim to create a national model for industry– academia partnerships that advance affordable, high-impact healthcare innovation and position India as a global leader in applied biotechnology.